vs
Side-by-side financial comparison of First Savings Financial Group, Inc. (FSFG) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.
First Savings Financial Group, Inc. is the larger business by last-quarter revenue ($1.5M vs $820.2K, roughly 1.8× InMed Pharmaceuticals Inc.). First Savings Financial Group, Inc. runs the higher net margin — 350.2% vs -247.3%, a 597.5% gap on every dollar of revenue. On growth, First Savings Financial Group, Inc. posted the faster year-over-year revenue change (-0.7% vs -26.2%). Over the past eight quarters, InMed Pharmaceuticals Inc.'s revenue compounded faster (-16.4% CAGR vs -70.2%).
The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
FSFG vs INM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $820.2K |
| Net Profit | $5.3M | $-2.0M |
| Gross Margin | — | 22.5% |
| Operating Margin | — | -247.3% |
| Net Margin | 350.2% | -247.3% |
| Revenue YoY | -0.7% | -26.2% |
| Net Profit YoY | 43.5% | 21.2% |
| EPS (diluted) | $0.76 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $820.2K | ||
| Q3 25 | $1.5M | $1.1M | ||
| Q2 25 | $1.4M | $1.3M | ||
| Q1 25 | $1.5M | $1.3M | ||
| Q4 24 | $1.5M | $1.1M | ||
| Q3 24 | $1.5M | $1.3M | ||
| Q2 24 | $1.4M | $1.3M | ||
| Q1 24 | $18.0M | $1.2M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $5.3M | $-1.7M | ||
| Q2 25 | $6.2M | $-1.8M | ||
| Q1 25 | $5.5M | $-2.1M | ||
| Q4 24 | $6.2M | $-2.6M | ||
| Q3 24 | $3.7M | $-1.7M | ||
| Q2 24 | $4.1M | $-1.9M | ||
| Q1 24 | $4.9M | $-1.7M |
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 36.0% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | — | 13.9% | ||
| Q4 24 | — | 41.5% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 36.3% | ||
| Q1 24 | — | 24.7% |
| Q4 25 | — | -247.3% | ||
| Q3 25 | — | -154.2% | ||
| Q2 25 | — | -137.1% | ||
| Q1 25 | — | -168.1% | ||
| Q4 24 | — | -231.6% | ||
| Q3 24 | — | -132.7% | ||
| Q2 24 | — | -150.5% | ||
| Q1 24 | 32.1% | -146.9% |
| Q4 25 | — | -247.3% | ||
| Q3 25 | 350.2% | -154.2% | ||
| Q2 25 | 441.1% | -137.1% | ||
| Q1 25 | 377.2% | -168.1% | ||
| Q4 24 | 424.0% | -231.6% | ||
| Q3 24 | 242.4% | -132.7% | ||
| Q2 24 | 295.8% | -151.0% | ||
| Q1 24 | 27.3% | -146.9% |
| Q4 25 | — | $-0.51 | ||
| Q3 25 | $0.76 | $-0.44 | ||
| Q2 25 | $0.88 | $-0.07 | ||
| Q1 25 | $0.79 | $-1.94 | ||
| Q4 24 | $0.89 | $-3.64 | ||
| Q3 24 | $0.53 | $-2.71 | ||
| Q2 24 | $0.60 | $2.39 | ||
| Q1 24 | $0.72 | $-3.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.9M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.5M | $9.6M |
| Total Assets | $2.4B | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.0M | ||
| Q3 25 | $31.9M | $9.4M | ||
| Q2 25 | $52.1M | $11.1M | ||
| Q1 25 | $28.7M | $4.7M | ||
| Q4 24 | $76.2M | $3.5M | ||
| Q3 24 | $52.1M | $5.6M | ||
| Q2 24 | $42.4M | $6.6M | ||
| Q1 24 | $63.0M | — |
| Q4 25 | — | $9.6M | ||
| Q3 25 | $193.5M | $11.6M | ||
| Q2 25 | $183.8M | $13.4M | ||
| Q1 25 | $179.2M | $7.0M | ||
| Q4 24 | $176.0M | $6.2M | ||
| Q3 24 | $177.1M | $8.4M | ||
| Q2 24 | $168.0M | $9.2M | ||
| Q1 24 | $165.1M | $11.1M |
| Q4 25 | — | $11.2M | ||
| Q3 25 | $2.4B | $13.4M | ||
| Q2 25 | $2.4B | $15.6M | ||
| Q1 25 | $2.4B | $9.3M | ||
| Q4 24 | $2.4B | $8.5M | ||
| Q3 24 | $2.5B | $10.5M | ||
| Q2 24 | $2.4B | $11.8M | ||
| Q1 24 | $2.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $79.1M | $-2.4M |
| Free Cash FlowOCF − Capex | $78.3M | — |
| FCF MarginFCF / Revenue | 5199.5% | — |
| Capex IntensityCapex / Revenue | 58.4% | — |
| Cash ConversionOCF / Net Profit | 15.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.4M | ||
| Q3 25 | $79.1M | $-1.6M | ||
| Q2 25 | $6.5M | $-1.8M | ||
| Q1 25 | $-32.8M | $-1.7M | ||
| Q4 24 | $177.0K | $-2.5M | ||
| Q3 24 | $91.2M | $-1.8M | ||
| Q2 24 | $-655.0K | $-1.0M | ||
| Q1 24 | $7.7M | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $6.5M | — | ||
| Q1 25 | $-32.9M | — | ||
| Q4 24 | $-347.0K | — | ||
| Q3 24 | $90.5M | — | ||
| Q2 24 | $-702.0K | — | ||
| Q1 24 | $7.7M | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | 5199.5% | — | ||
| Q2 25 | 462.7% | — | ||
| Q1 25 | -2258.8% | — | ||
| Q4 24 | -23.6% | — | ||
| Q3 24 | 5974.9% | — | ||
| Q2 24 | -51.0% | — | ||
| Q1 24 | 42.6% | -165.0% |
| Q4 25 | — | — | ||
| Q3 25 | 58.4% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 45.1% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 0.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 15.01× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | -5.97× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 24.84× | — | ||
| Q2 24 | -0.16× | — | ||
| Q1 24 | 1.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
